Insulin resistance — the failure of cells to respond normally to insulin signaling — drives type 2 diabetes, PCOS, metabolic syndrome, and accelerated aging. It involves impaired GLUT4 translocation, mitochondrial dysfunction in muscle and fat cells, chronic visceral adipose inflammation, and dysregulated incretin signaling. Peptide research targets each of these mechanisms.
1. Semaglutide — GLP-1 Mediated Insulin Sensitization
Semaglutide enhances incretin signaling, which restores the first-phase insulin response lost in insulin resistance, suppresses glucagon-driven hepatic glucose output, and reduces postprandial glucose excursions. Clinical data shows significant improvements in insulin sensitivity indices alongside the well-documented weight loss effects.
Dosing Protocol: 0.25 mg SubQ once weekly. Titrate by 0.25 mg every 4 weeks to 1–2.4 mg/week based on goals and tolerance.
2. MOTS-C — AMPK Activation / Muscle Glucose Uptake
MOTS-C activates AMPK in skeletal muscle — the same pathway activated by exercise — promoting GLUT4 translocation and glucose uptake independent of insulin. In insulin-resistant states, MOTS-C restores cellular glucose disposal capacity by bypassing the defective insulin receptor signaling, effectively acting as an insulin sensitizer at the mitochondrial level.
Dosing Protocol: 5–10 mg SubQ 3–5x per week. Best timed around physical activity. Cycle: 4–8 weeks.
3. BPC-157 — Pancreatic Protection / Gut-Metabolic Axis
Chronic insulin resistance damages pancreatic beta cells through glucotoxicity and lipotoxicity. BPC-157 provides direct cytoprotection to beta cells, reduces pancreatic inflammation, and addresses gut permeability-driven metabolic endotoxemia — a major but underappreciated driver of systemic insulin resistance.
Dosing Protocol: 250–500 mcg SubQ daily, or 500 mcg oral (arginate) for gut-metabolic axis targeting. Cycle: 8–12 weeks.
4. Tirzepatide — Dual Agonist / Adipose Insulin Sensitivity
Tirzepatide’s dual GIP/GLP-1 mechanism provides superior insulin sensitization compared to GLP-1 alone. GIP receptor activation directly improves adipose tissue insulin sensitivity, reducing the visceral fat-driven free fatty acid flux that impairs hepatic and muscle insulin signaling.
Dosing Protocol: 2.5 mg SubQ once weekly. Titrate by 2.5 mg every 4 weeks to 5–15 mg/week.
Semaglutide and Tirzepatide correct incretin deficiency — the hormonal root of deteriorating insulin secretion and sensitivity. MOTS-C provides a parallel insulin-independent glucose disposal pathway in muscle. BPC-157 protects the pancreatic beta cells and addresses gut-driven metabolic inflammation that perpetuates insulin resistance even with dietary correction.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).